Knowledge Tree
high-sensitivity C-reactive protein
Also known as: hsCRP, hs-CRP, highly sensitive C-reactive protein
Facts (35)
Sources
EBM Tools for Practice: Best Biomarkers for Inflammation lipid.org 19 facts
measurementIn the Canakinumab Anti-inflammatory Thrombosis Outcome Trial (CANTOS), lowering high-sensitivity C-reactive protein (hs-CRP) below 2 mg/L resulted in a 25% reduction in major adverse cardiovascular events (p<0.001) and a 31% reduction in cardiovascular mortality (p<0.0001), despite no change in low-density lipoprotein cholesterol (LDL-C).
claimIn the Aggrastat-to-Zocor (A to Z) Trial, achieved levels of high-sensitivity C-reactive protein (hs-CRP) at 30 days and four months were independently associated with long-term survival and the risk of myocardial infarction (MI).
claimIn the Physicians’ Health Study, interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) demonstrated similar predictive risk for future myocardial infarction.
claimHigh-sensitivity C-reactive protein (hs-CRP) is the only inflammatory marker able to predict therapeutic success and is the only one recommended for measurement by the 2013 ACC/AHA guidelines.
claimIn the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), on-treatment high-sensitivity C-reactive protein (hs-CRP) levels following statin treatment predicted subsequent cardiovascular risk reductions.
claimThe Safety and Cardiovascular Event Efficacy of Bococizumab in High-Risk Patients (SPIRES) Trial showed that persistent elevation of high-sensitivity C-reactive protein (hs-CRP) at 14 weeks was associated with increased future cardiovascular events, even after low levels of low-density lipoprotein cholesterol (LDL-C) were achieved.
claimThe 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend measuring high-sensitivity C-reactive protein (hs-CRP) when treatment decisions are uncertain based on global risk scoring.
claimInterleukin-6 (IL-6) is less predictive than high-sensitivity C-reactive protein (hs-CRP) in head-to-head comparisons and is less accessible for the practicing clinician.
claimIn the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial, the baseline level of high-sensitivity C-reactive protein (hs-CRP) predicted which patients were at the greatest risk for cardiovascular events.
claimIn the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), patients experienced the fewest cardiovascular events when achieving both a low-density lipoprotein cholesterol (LDL-C) <70 mg/dL and a high-sensitivity C-reactive protein (hs-CRP) <2 mg/L.
claimIn a direct comparison of a panel of inflammatory markers (including serum amyloid A, IL-6, and soluble intercellular adhesion molecule type 1 [sICAM-1]) and various lipid markers, high-sensitivity C-reactive protein (hs-CRP) surpassed all of them as a predictor of cardiovascular events.
claimAchieved levels of high-sensitivity C-reactive protein (hs-CRP) during treatment are a strong predictor of subsequent clinical outcomes.
claimMyeloperoxidase (MPO) could be helpful as a complementary marker of risk alongside high-sensitivity C-reactive protein (hs-CRP), but it is less effective as a single marker.
claimThe Reversing Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial reported that regression of vascular disease occurred only in the group of patients who achieved low levels of both low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP).
claimElevated levels of high-sensitivity C-reactive protein (hs-CRP) among healthy individuals is a strong predictor of future cardiovascular events, with a two to four-fold increase in risk comparing the top versus bottom tertile, independently of age, gender, and cholesterol levels.
claimThe Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) and the Pravastatin or Atorvastatin Evaluation and Infection Therapy Trial (PROVE-IT) showed that patients who met both targets of low-density lipoprotein cholesterol (LDL-C) <70 mg/dL and high-sensitivity C-reactive protein (hs-CRP) <2 mg/L had the best clinical outcomes.
measurementIn patients with coronary artery disease (CAD), high-sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO) are each predictive for cardiovascular mortality, and patients with elevated levels of both markers experience a 4.33-fold increase in risk.
claimLipoprotein-associated phospholipase A2 (Lp-PLA2) can be used to evaluate risk in statin-naïve patients for primary prevention and may be helpful as a complementary marker of risk alongside high-sensitivity C-reactive protein (hs-CRP), but it is not designed as a goal of therapy or for risk prediction in secondary prevention.
claimThe addition of high-sensitivity C-reactive protein (hs-CRP) to the Reynolds Risk Score has shown improved ability to estimate 10-year cardiovascular risk.
Chronic Inflammation - StatPearls - NCBI Bookshelf ncbi.nlm.nih.gov 6 facts
claimMagnesium intake is associated with the lowering of high-sensitivity C-reactive protein (hsCRP), IL-6, and TNF-alpha activity.
claimHigh-sensitivity C-reactive protein (hsCRP) is not a specific marker for chronic inflammation because it is also elevated in acute inflammation resulting from recent injury or sickness.
claimClinical studies have shown strong and consistent relationships between inflammatory markers, such as high-sensitivity C-reactive protein (hsCRP), and the prediction of cardiovascular disease.
measurementThe normal serum level for high-sensitivity C-reactive protein (hsCRP) is less than 0.55 mg/L in men and less than 1.0 mg/L in women.
claimHigh-sensitivity C-reactive protein (hsCRP) and fibrinogen are inexpensive blood tests that serve as markers of systemic inflammation.
claimCardiovascular disease is strongly and consistently predicted by inflammatory markers such as high-sensitivity C-reactive protein (hsCRP).
Tracking Inflammation Through Biomarkers rupahealth.com Jul 24, 2024 5 facts
claimHigh-sensitivity C-reactive protein (hs-CRP) is a biomarker utilized for risk assessment and management of cardiovascular conditions like heart attacks and strokes.
claimElevated high-sensitivity C-reactive protein (hs-CRP) levels indicate inflammation associated with atherosclerosis and increased cardiovascular risk, which prompts early intervention to reduce the risk of future adverse cardiac events.
claimHigh-sensitivity C-reactive protein (hs-CRP) is primarily used in cardiovascular risk assessment.
claimHigh-sensitivity C-reactive protein (hs-CRP) is a more sensitive test than standard C-reactive protein (CRP) tests, allowing for the detection of low levels of CRP and minor elevations associated with chronic, low-grade inflammation.
claimPersistently high levels of biomarkers such as erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hs-CRP) often indicate chronic inflammation associated with ongoing conditions like autoimmune diseases and chronic infections.
Editorial: Inflammation and chronic disease - Frontiers frontiersin.org Jul 1, 2024 2 facts
claimUS adults with undiagnosed cardiometabolic disease have a higher risk of elevated highly sensitive C-reactive protein (HsCRP) levels, according to Mainous, Sharma et al.
claimA considerable proportion of US adults, particularly minorities and individuals with low socioeconomic status, have elevated inflammation as measured by highly sensitive C-reactive protein (HsCRP), according to Mainous, Orlando et al.
Inflammatory Markers | Choose the Right Test arupconsult.com Jun 16, 2025 1 fact
claimHigh-sensitivity C-Reactive Protein (hsCRP) is not used for the same purposes as C-Reactive Protein (CRP) and should not be used in the assessment of general inflammatory processes.
Origins and evolution of the Western diet: health implications for the ... academia.edu 1 fact
referenceLiu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, and Ridker PM found a relationship between diets with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women, as published in the American Journal of Clinical Nutrition in 2002.
Chronic inflammation in the etiology of disease across the life span nature.com Dec 5, 2019 1 fact
referenceHigh-sensitivity C-reactive protein is a biomarker used to assess inflammation in the context of cardiovascular risk, as detailed by Ridker (2016).